Compare PulteGroup, Inc. (PHM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.

The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.